More biosimilars have been marketed in Germany and Switzerland than in the United States, however uptake has elevated over time in all international locations, in accordance with a examine printed on-line Dec. 2 in JAMA Network Open.
David L. Carl, from the University of Zurich, and colleagues examined uptake and costs of biosimilars in the United States versus Germany and Switzerland in a cohort examine. For 2011 to 2020, costs and gross sales information have been extracted from public and industrial databases.
The examine cohort included 15 biosimilars and 6 biologics for the United States; 52 and 15 for Germany; and 28 and 13 for Switzerland. The researchers discovered that in all international locations, uptake of biosimilars elevated over time. On common, the very best biosimilar market share at launch was seen in Germany; nevertheless, in the United States, it elevated on the quickest fee. Monthly remedy prices of biosimilars have been a median of 1.94 and a couple of.74 greater in the United States versus the corresponding prices in Germany and Switzerland.
“Policies for drug pricing negotiations in the United States against anticompetitive practices of exclusionary contracts could allow biosimilars to enter the market sooner and at lower costs, which could result in lower health care costs and improved patient access,” the authors write. “Awareness of biosimilars should be promoted to increase the uptake of biosimilars in all three countries.”
Abstract/Full Text
Copyright © 2022 HealthDay. All rights reserved.
Citation:
More biosimilars marketed in Germany, Switzerland than U.S. (2022, December 2)
retrieved 2 December 2022
from https://medicalxpress.com/news/2022-12-biosimilars-germany-switzerland.html
This doc is topic to copyright. Apart from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
More biosimilars marketed in Germany, Switzerland than U.S.
More biosimilars marketed in Germany, Switzerland than U.S.
info with out going via us first, so we are able to present you the newest and biggest information with out costing you a dime. The two of it’s possible you’ll study the specifics of the information collectively, supplying you with a leg up. We’ll get to the following step when a bit of time has gone.
Our objective is to maintain you recent on all the latest information from across the globe by posting related articles on our web site, so that you could be at all times be one step forward. In this way, you will by no means fall behind the newest developments in that information.
More biosimilars marketed in Germany, Switzerland than U.S.